CDL Cancer Track

Recursive Health is Selected to the Cancer Track in the 2024 Creative Destruction Lab Cohort

We’re In!

Recursive Health is excited to announce our acceptance into the Creative Destruction Lab (CDL) Cancer track! This opportunity connects us with world-class leaders in cancer care, through partnerships with the Canadian Cancer Society and New York University, as well as global leaders in technology and healthcare innovation, including Microsoft and Novartis.

Why This Matters

The Creative Destruction Lab is a force in healthcare and technology innovation. Over 1,700 world-changing companies have graduated as portfolio cohort members, boasting the creation of more than $32 billion in cumulative enterprise value.

What We’re Gaining from CDL Cancer

• Collaboration with the Canadian Cancer Society and other strategic partners, ensuring our innovations align with global cancer care priorities.

• Interface with Microsoft and Novartis, giving us access to cutting-edge technology and insights from leaders in healthcare and AI.

• Mentorship from some of the most experienced minds in cancer treatment and healthcare innovation at NYU and MD Anderson, guiding us as we refine our solutions and scale our impact.

What’s Next?

Over the next nine months, we’ll work closely with CDL mentors and partners to advance our AI-enabled platform. We’re thrilled to be part of this journey and look forward to sharing more as we continue our work to transform preventive cancer screening.

Onward!

Brandon C. Busuito, M.D., M.B.A.

Co-founder, CEO